Aktieinformation Addex Therapeutics | Filter  Basic-Info

Addex Therapeutics

Between 2006 and 2016 the global biotech companies gained around 59 percent. As from 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The Swiss company didn't pay out any dividends (in the past 5 years).

Addex Therapeutics had about 210 employees at the end of 2015.

Addex Therapeutics' balance mostly financed with equity

At the end of 2015 the Swiss company's balance sheet was worth 2,89 million CHFF. Last year the total debt of the company was 1,23 million CHFF. This equals around 42,56 percent of the total balance sheet. The Swiss company's price/earnings-ratio was -9. So the market valued the stock at -9 times the 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the Swiss stock can be seen as a value stock.

At the end of 2015 the biotech company's market capitalization (the number of shares times the market price) equaled around 33,21 million CHFF. At the end of 2015 the Swiss company had around 10,85 million stocks listed on the stock exchange(s).

All Addex Therapeutics's annual reports can be found here. More information about Addex Therapeutics can be found it's website. .